LifeScan said yesterday that it entered into an agreement with Willis Towers Watson to expand the commercialization of its OneTouch Reveal Plus digital diabetes therapy system.
The companies hope the collaboration will see LifeScan and Willis Towers Watson combine to support self-insured employers in helping their employees and dependents manage diabetes.
The OneTouch Reveal Plus is indicated for use with adult patients who have Type 2 diabetes. The device is designed to provide patients with individualized, real-time feedback and virtual coaching, based on a specific treatment plan. It also offers weekly challenges, meal planning tools, an insulin calculator, connectivity with popular fitness trackers and a comprehensive smart visit report for sharing with a healthcare team.
The device is powered by Welldoc’s BlueStar platform. LifeScan said it is working with Welldoc to expand the app’s capabilities and connectivity in the hopes of earning FDA clearance for treating Type 1 diabetes, as well as other potential conditions.
“We are excited that through this partnership with Willis Towers Watson we will be able to offer OneTouch Reveal Plus to employers who are looking to help their employees and their families live healthier lives and better manage diabetes,” LifeScan CEO & president Val Asbury said in prepared remarks.
LifeScan was operated by Johnson & Johnson (NYSE:JNJ) before private equity shop Platinum Equity paid $2.1 billion offer for the blood glucose monitoring business in June 2018.